- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07862569
DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg
A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Doravirine/Islatravir (100 mg/0.25 mg) in Pediatric Participants With HIV-1 Infection Who Are Virologically Suppressed or Treatment-Naïve, Are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg
This is a phase 2 study of the pharmacokinetics, safety, and efficacy of oral doravirine/islatravir (100 mg/0.25 mg) [MK-8591A] in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection who are virologically suppressed or treatment-naive.
The Base Study will last from Day 1 to Week 96. At Week 96, participants will be given the option to participate in an optional Study Extension and receive DOR/ISL until Week 240 or until it becomes commercially accessible, whichever is first.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Toll Free Number
- Telefonnummer: 1-888-577-8839
- E-post: Trialsites@merck.com
Studiesteder
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- University of South Florida ( Site 1505)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 813-821-8039
-
-
New York
-
The Bronx, New York, Forente stater, 10467
- The Children's Hospital at Montefiore ( Site 1507)
-
Ta kontakt med:
- Study Coordinator
- Telefonnummer: 718-741-2497
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Pediatric participant with HIV-1 <18 years of age
- Body weight ≥35 kg
- Is TN (HIV-1 positive with plasma HIV-1 RNA ≥500 copies/mL) or VS (HIV-1 positive at screening with plasma HIV-1 RNA <50 copies/mL AND has received stable, continuous 2- or 3-drug antiretroviral therapy (ART) for ≥3 months prior to providing informed consent)
Exclusion Criteria:
- HIV-2 infection
- Hypsensitivity/contraindication to any components of study medication or as determined by the investigator
- Has an active diagnosis of hepatitis due to any cause
- history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
- Has a history or current evidence of any condition (including active tuberculosis infection, COVID-19, or other infections), therapy, laboratory abnormality, or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study
- Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or any prohibited therapies
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: DOR/ISL
Participants receive DOR/ISL 100 mg/0.25 mg once daily (qd) for 96 weeks. Participants will have the option to participate in the Study Extension and receive DOR/ISL until Week 240 or it becomes commercially available, whichever is first. |
DOR/ISL 100 mg/0.25 mg tablet taken by mouth qd
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Area under the plasma conentration-time curve from dosing to 24 hours postdose (AUC0-24) of ISL
Tidsramme: At designated timepoints on Day 28
|
The plasma AUC0-24 will be assessed. |
At designated timepoints on Day 28
|
|
Maximum plasma concentration (Cmax) of ISL
Tidsramme: At designated timepoints on Day 28
|
The plasma Cmax will be assessed. |
At designated timepoints on Day 28
|
|
Time to maximum plasma concentration (Tmax) of ISL
Tidsramme: At designated timepoints on Day 28
|
The plasma Tmax will be assessed. |
At designated timepoints on Day 28
|
|
Apparent plasma terminal half-life (t½) of ISL
Tidsramme: At designated timepoints on Day 28
|
The plasma t½ will be assessed. |
At designated timepoints on Day 28
|
|
Apparent clearance (CL/F) of ISL
Tidsramme: At designated timepoints on Day 28
|
The CL/F will be assessed. |
At designated timepoints on Day 28
|
|
Volume of distribution (Vz/F) of ISL
Tidsramme: At designated timepoints on Day 28
|
The Vz/F will be assessed. |
At designated timepoints on Day 28
|
|
Percentage of participants with ≥1 adverse event (AE) through Week 24
Tidsramme: Up to ~24 weeks
|
The percentage of participants with AE(s) will be assessed. |
Up to ~24 weeks
|
|
Percentage of participants discontinuing from study therapy due to AE(s) through Week 24
Tidsramme: Up to ~24 weeks
|
The percentage of participants discontinuing from therapy due to AE(s) will be assessed. |
Up to ~24 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of participants with ≥1 AE through Week 96
Tidsramme: Up to 96 weeks
|
The percentage of participants with AE(s) will be assessed. |
Up to 96 weeks
|
|
Percentage of participants discontinuing from study therapy due to AE(s) through Week 96
Tidsramme: Up to 96 weeks
|
The percentage of participants with AE(s) will be assessed. |
Up to 96 weeks
|
|
Percentage of virologically-suppressed (VS) participants with Human Immunodeficiency Virus Type 1 (HIV-1) ribonucleic acid (RNA) ≥50 copies/mL
Tidsramme: Weeks 24, 48, and 96
|
The percentage of VS participants with HIV-1 RNA ≥50 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of VS participants with HIV-1 RNA <50 copies/mL
Tidsramme: Weeks 24, 48, and 96
|
The percentage of VS participants with HIV-1 RNA <50 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of VS participants with HIV-1 RNA <200 copies/mL
Tidsramme: Weeks 24, 48, and 96
|
The percentage of VS participants with HIV-1 RNA <200 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of treatment-naive (TN) participants with HIV-1 RNA <50 copies/mL
Tidsramme: Weeks 24, 48, and 96
|
The percentage of TN participants with HIV-1 RNA <50 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Percentage of TN participants with HIV-1 RNA <200 copies/mL
Tidsramme: Weeks 24, 48, and 96
|
The percentage of TN participants with HIV-1 RNA <200 copies/mL will be assessed. |
Weeks 24, 48, and 96
|
|
Change from baseline in CD4+ T-cell counts in VS and TN participants
Tidsramme: Weeks 24, 48, and 96
|
The change from baseline in CD4+ T-cell counts will be assessed in VS and TN participants. |
Weeks 24, 48, and 96
|
|
Percentage of participants with viral drug resistance to DOR or ISL
Tidsramme: Weeks 24, 48, 96, and 144
|
The percentage of participants with viral resistance-associated substitutions will be assessed during Weeks 24, 48, 96, and 144. |
Weeks 24, 48, 96, and 144
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Blodbårne infeksjoner
- Urogenitale sykdommer
- Kjønnssykdommer
- Sykdommer i immunsystemet
- Infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Seksuelt overførbare sykdommer
- Lentivirus infeksjoner
- Retroviridae-infeksjoner
- Immunologiske mangelsyndromer
- HIV-infeksjoner
Andre studie-ID-numre
- 8591A-063
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .